Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 18;104(10):e43.
doi: 10.2106/JBJS.21.00832. Epub 2021 Dec 13.

Hyaluronic Acid Injections for Knee Osteoarthritis: Has Utilization Among Medicare Beneficiaries Changed Between 2012 and 2018?

Kevin Y Zhu  1 , Alexander J Acuña, Linsen T Samuel, Daniel Grits, Atul F Kamath
Affiliations

Hyaluronic Acid Injections for Knee Osteoarthritis: Has Utilization Among Medicare Beneficiaries Changed Between 2012 and 2018?

Kevin Y Zhu et al. J Bone Joint Surg Am. .

Abstract

Background: The utilization of hyaluronic acid (HA) for the management of knee osteoarthritis (OA) remains controversial, and more information is needed regarding how its utilization and financial burden have changed over recent years. The purpose of our analysis was to evaluate changes in overall utilization and health-care costs associated with HA injections among Medicare beneficiaries over a contemporary time frame.

Methods: The 2012 to 2018 Medicare Fee-for-Service Provider Utilization and Payment Public Use Files (PUFs) were utilized for our analysis. Organized by Healthcare Common Procedure Coding System (HCPCS) codes, these files capture 100% of Medicare Part B claims. Payment and utilization data were collected for all HCPCS codes corresponding to injection of an HA formulation. The number of services involving HA as well as the total cost of HA administration in 2020 U.S. dollars were tabulated. Mann-Kendall trend tests were used to evaluate trends in utilization for providers nationally and when segregated by specialty.

Results: Total HA utilization increased significantly from 2012 (n = 1,090,503) through 2018 (n = 1,209,489; p = 0.04). Although orthopaedic surgeons did not demonstrate significant changes in total utilization rates (p = 0.23), the average number of services per orthopaedic surgeon increased significantly (p = 0.02). Reflecting a substantial growth in the number of advanced practice providers (APPs) providing injections, there was a significant increase in utilization and associated costs among physician assistants (p < 0.01) and nurse practitioners (p < 0.01). Total costs associated with HA services increased significantly from $290.10 million to $325.02 million (p < 0.01).

Conclusions: Despite the 2013 American Academy of Orthopaedic Surgeons clinical practice guideline recommending against the clinical utility of these injections, HA services continued to be widely implemented among Medicare beneficiaries. Although there were variations across specialties when evaluating overall utilization rates as well as rates per provider, APPs largely contributed to the increase seen in the U.S. over this study period. More data are needed to support continued implementation and spending on this low-value care.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJS/G820).

Comment in

References

    1. CJL Murray, C Atkinson, K Bhalla, G Birbeck, R Burstein, D Chou, R Dellavalle, G Danaei, M Ezzati, A Fahimi, Foreman Flaxman D, S Gabriel, E Gakidou, N Kassebaum, S Khatibzadeh, S Lim, Lipshultz SE, Lopez London S, MacIntyre MF, AH Mokdad, A Moran, AE Moran, D Mozaffarian, Murphy T, M Naghavi, C Pope, T Roberts, J Salomon, Schwebel DC, S Shahraz, DA Murray Sleet, J Abraham, MK Ali, C Atkinson, DH Bartels, K Bhalla, G Birbeck, R Burstein, H Chen, MH Criqui, Jarlais Dahodwala, EL Ding, Dorsey ER, Ebel BE, Fahami Ezzati M, S Flaxman, AD Flaxman, Gonzalez-Medina D, B Grant, H Hagan, H Hoffman, N Kassebaum, S Khatibzadeh, JL Leasher, J Lin, SE Lipshultz, R Lozano, Y Lu, L Mallinger, MM McDermott, R Micha, TR Miller, AA Mokdad, AH Mokdad, D Mozaffarian, M Naghavi, KM Narayan, SB Omer, PM Pelizzari, D Phillips, D Ranganathan, FP Rivara, T Roberts, U Sampson, E Sanman, A Sapkota, DC Schwebel, S Sharaz, R Shivakoti, GM Shivakoti, D Singh, M Tavakkoli, JA Towbin, Wilkinson JD, Murray Zabetian A, J Abraham, MK Ali, M Alvardo, C Atkinson, LM Baddour, EJ Benjamin, K Bhalla, G Birbeck, I Bolliger, R Burstein, E Carnahan, D Chou, SS Chugh, A Cohen, KE Colson, LT Cooper, W Couser, MH Criqui, KC Dabhadkar, RP Dellavalle, Jarlais, D Dicker, ER Dorsey, H Duber, Ebel BE, RE Engell, M Ezzati, DT Felson, MM Finucane, S Flaxman, AD Flaxman, Foreman Fleming T, Forouzanfar MH, G Freedman, MK Freeman, E Gakidou, RF Gillum, Gonzalez-Medina D, R Gosselin, HR Gutierrez, H Hagan, R Havmoeller, H Hoffman, KH Jacobsen, SL James, R Jasrasaria, S Jayarman, N Johns, N Kassebaum, Khatibzadeh S, Lan Q, Leasher JL, Lim S, Lipshultz SE, London S Lopez, Lozano R, Lu Y, Mallinger L, Meltzer M, Mensah GA, Michaud C, Miller TR, Mock C, Moffitt TE, Mokdad AA, Mokdad AH, Moran A, Naghavi M, Narayan KM, Nelson RG, Olives C, Omer SB, Ortblad K, Ostro B, Pelizzari PM, Phillips D, Raju M, Razavi H, Ritz B, Roberts T, Sacco RL, Salomon J, Sampson U, Schwebel DC, Shahraz S, Shibuya K, Silberberg D, Singh JA, K Steenland, Taylor JA, GD Thurston, Vavilala MS, T Vos, GR Wagner, Weinstock MA, MG Weisskopf, S Wulf, Murray; U.S. Burden of Disease Collaborators. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013 Aug 14;310(6):591-1-8.
    1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1545-1-8.
    1. Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020 Nov 26;29-1-8:100587.
    1. Ondrésik M, Azevedo Maia FR, da Silva Morais A, Gertrudes AC, Dias Bacelar AH, Correia C, Gonçalves C, Radhouani H, Amandi Sousa R, Oliveira JM, Reis RL. Management of knee osteoarthritis. Current status and future trends. Biotechnol Bioeng. 2017 Apr;114(4):717-1-8.
    1. Weick JW, Bawa HS, Dirschl DR. Hyaluronic Acid Injections for Treatment of Advanced Osteoarthritis of the Knee: Utilization and Cost in a National Population Sample. J Bone Joint Surg Am. 2016 Sep 7;98(17):1429-1-8.

Substances

LinkOut - more resources